BMS 310705

Drug Profile

BMS 310705

Alternative Names: BMS310705

Latest Information Update: 13 Oct 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb; GBF
  • Developer Bristol-Myers Squibb; Helmholtz Centre for Infection Research GmbH
  • Class Antineoplastics; Epothilones; Macrolides
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Aug 2005 A preclinical study has been added to the pharmacokinetics section
  • 05 Nov 2003 A study has been added to the adverse events and Cancer therapeutic trials sections
  • 04 Jul 2003 Data presented at the 39th Annual Meeting of the Society of Clinical Oncology (ASCO-2003) have been added to the adverse events, pharmacokinetics, Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top